A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa.

Trial Profile

A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2014

At a glance

  • Drugs ICX-RHY (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Sponsors Intercytex
  • Most Recent Events

    • 03 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top